Drug Database
FO

folic acid + vitamin B6 + vitamin B12 + primorine (Folmor)

✓ Approved

Zylera · 小分子 · 小分子

什么是 folic acid + vitamin B6 + vitamin B12 + primorine?

folic acid + vitamin B6 + vitamin B12 + primorine 是一种小分子,由Zylera研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名Folmor
公司Zylera
药物类别小分子
给药途径Unknown
状态Approved

治疗适应症

folic acid + vitamin B6 + vitamin B12 + primorine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved

相关研究文献

PubMedJournal of orthopaedic surgery and research2026-11-19

Vitamin D in spine disorders: mechanisms, clinical evidence, and translational gaps-a narrative review.

Zhang Feng F, Bai Yun Y

Vitamin D has been increasingly implicated in the pathophysiology of spine disorders, yet its clinical utility remains uncertain. Across a broad spectrum of conditions, including intervertebral disc degeneration, chronic low back pain, lumbar spinal stenosis, spinal deformities, and surgical populations, vitamin D deficiency is highly prevalent. Mechanistically, vitamin D exerts pleiotropic effects through the vitamin D receptor, regulating inflammatory signaling, extracellular matrix homeostasis, oxidative stress, and ferroptosis, while also influencing paraspinal muscle biology, and genetic studies suggest that vitamin D receptor polymorphisms may contribute to inter-individual variability in disease susceptibility and cellular response. Despite strong biological plausibility and consistent observational associations, clinical evidence remains heterogeneous. In degenerative and pain-related conditions, randomized trials and meta-analyses do not demonstrate a consistent benefit of supplementation for pain relief or disease modification in unselected populations. In contrast, perioperative spine settings provide more promising findings, with deficiency associated with delayed fusion, poorer functional outcomes, and higher complication risk, while supplementation may improve intermediate-term recovery in selected patients. Across specific conditions such as lumbar spinal stenosis, adolescent idiopathic scoliosis, and axial spondyloarthritis, results remain inconsistent, and current evidence does not support routine supplementation for disease modification. Similarly, although low vitamin D levels are associated with increased risk of osteoporotic vertebral fractures, supplementation has not consistently improved fracture-related outcomes. Overall, vitamin D is best considered a modifiable comorbidity rather than a primary therapeutic target, and a targeted approach focused on deficient or high-risk individuals, particularly in perioperative contexts, appears more appropriate than universal supplementation. Future research should prioritize well-designed trials in deficient populations and precision-based strategies to clarify its role in spine care.

PMID 43053138
阅读全文 →
PubMedCritical care (London, England)2026-11-19

Effect of megadose vitamin C in patients with sepsis: the CEMVIS randomized clinical trial.

Guan Jianbin J, Wang Guizhong G, Liang Zhihui Z, Peng Wei W et al.

Previous randomized trials of vitamin C in sepsis have reported conflicting findings, but whether the effect of vitamin C varies according to septic shock status remains unclear. We aimed to evaluate the effect of megadose vitamin C in sepsis and explore whether treatment effect differed according to septic shock status. CEMVIS was a multicenter, randomized, single-blind, placebo-controlled trial conducted in four tertiary hospitals in China. Adults meeting Sepsis-3 criteria were randomly assigned (1:1) to receive intravenous vitamin C (12 g every 12 h for 4 days) or placebo using stratified randomization according to septic shock status. Patients were analyzed according to the modified intention-to-treat principle. The primary outcome was 28-day mortality. Between Feb 8, 2022, and Dec 25, 2024, 114 patients in the vitamin C group and 117 in the placebo group were included in the modified intention-to-treat population. 28-day mortality did not differ significantly between groups (35/114 [30.7%] vs 36/116 [31.0%]; odds ratio 0.99, 95% CI 0.56-1.74; p = 0.97). No significant differences were observed in the duration of mechanical ventilation, vasopressor therapy, and renal replacement therapy, or in changes in SOFA scores over 96 hours. Prespecified subgroup analyses showed significant interaction according to septic shock status (P for interaction = 0.026), with the treatment effects on 28-day mortality numerically favoring vitamin C among patients without septic shock (15.4% vs 34%) and numerically favoring placebo among those with septic shock (38.7% vs 29%). Hypernatremia occurred more frequently in the vitamin C group (40/114 [35.1%] vs 24/117 [20.5%]; p = 0.02). Exploratory restricted cubic spline analyses showed that increasing lactate levels were associated with a progressive shift in treatment effect from potential benefit toward potential harm. Post hoc Bayesian analyses further provided probabilistic characterization of the potential treatment effect according to septic shock status. The results of this trial do not support the routine use of megadose vitamin C to reduce 28-day mortality in patients with sepsis. Treatment effects may vary according to septic shock status. This trial was registered with ClinicalTrials.gov on 3 January 2022 (identifier: NCT05194189).

PMID 43053147
阅读全文 →
PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-11-19

Protective effects of intermittent fasting and vitamin E against hyperthyroidism-associated ocular complications in Wistar rats.

Kumar Nirdesh N, Kumari Nidhi N, Singh Geeta G, Singh Beyant B et al.

Our study endeavours to prevent hyperthyroidism-associated ocular complications through the synergy of intermittent fasting and vitamin E supplementation. Our aim was to reduce the incidence of hyperthyroidism-associated ocular complications by combining these two interventions, while carefully monitoring dietary intake and supplementing with vitamin E. In this experiment, animals were divided into normal, hyperthyroidism control, dual, vitamin E, and intermittent fasting groups. Hyperthyroidism was induced by administering thyroxine for 24 days. Animals in the treatment groups took vitamin E and practised intermittent fasting. Intraocular pressure was measured weekly during the protocol. After the protocol, antioxidant status, malondialdehyde and nitrite level, protein content, retinal pictures, histopathology of lens and thyroid profile were analysed. Rats with hyperthyroidism control exhibited elevated (p < 0.001) intraocular pressure, lipid peroxidation, total protein content, and thyroid hormone levels, while antioxidant and nitrite levels decreased (p < 0.001). However, our non-drug therapy significantly (p < 0.001) improved all of these parameters, bringing them to their optimum levels. Intermittent fasting prevented ocular disease caused by hyperthyroidism by reducing oxidative stress and fibro genic matter deposition, and modulating nitrite balance. It works best when combined with vitamin E for superior antioxidant benefits. Our proposed remedies not only improved ocular function but also provided physiological benefits, suggesting a link to metabolic, ophthalmic, and neurogenic diseases in future projections.

PMID 43052389
阅读全文 →
PubMedNPJ biofilms and microbiomes2026-11-19

Modulation of gut microbiota by nardosinone augments the efficacy of levodopa in rotenone-induced Parkinson's disease rats.

Liu Mengmeng M, Xue Jingwen J, Cao Yuxin Y, Hao Zhuangzhuang Z et al.

Levodopa (L-DOPA) is the mainstay treatment for Parkinson's disease (PD), but its long-term use can cause adverse effects. Nardosinone enhances L-DOPA efficacy, yet the underlying mechanism is unclear. This study investigated whether the gut microbiota is associated with this synergism in a rotenone-induced PD rat model. Coadministration of nardosinone and L-DOPA increased L-DOPA and dopamine levels in the feces, plasma, and striatum of normal rats but not in antibiotic-treated rats with perturbed gut microbiota, suggesting a microbiota-correlated effect. Fecal microbiota transplantation from donors receiving the combination therapy alleviated motor deficits and dopaminergic neuron loss in recipient PD rats. This combination was associated with upregulated expression of tyrosine hydroxylase, DOPA decarboxylase, and their cofactors tetrahydrobiopterin and vitamin B6, as well as increased PINK1 and Parkin levels. It also reshaped the gut microbiota composition, enhanced intestinal and blood-brain barrier tight junction protein expression, and reduced c-Jun N-terminal kinase protein expression and neuroinflammation. In conclusion, these findings indicate that nardosinone coadministration is associated with alterations in the gut microbiota, improved barrier integrity markers, attenuated inflammation, and enhanced therapeutic effects of L-DOPA in this PD rat model. Definitive mechanistic pathways underlying the observed associations remain to be established.

PMID 43052303
阅读全文 →
PubMedBMC microbiology2026-11-19

Bioactive composition and in vitro bioactivity of postbiotics from mixed probiotic cultures: antimicrobial, antioxidant, and antidiabetic effects.

Asefa Zerihun Z, Belay Abera A, Damto Teferi T, Addi Admasu A et al.

Postbiotics, bioactive metabolites produced during probiotic fermentation, are increasingly recognized for their health-promoting properties and potential applications in functional foods and natural biopreservation. This study evaluated the bioactive composition and in vitro bioactivities of postbiotics derived from defined mixed cultures of Lacticaseibacillus rhamnosus GG (ATCC 53103), Lactiplantibacillus plantarum (DSM 9843), Bifidobacterium longum (35624), and Bifidobacterium breve (DSM 16604). Freeze-dried postbiotics were quantified gravimetrically, and their composition analyzed for exopolysaccharides (EPS), titratable acidity, B-vitamin content, fatty acid profiles, and amino acid composition using standard methods. In vitro bioactivities, including antioxidant capacity, antidiabetic potential via α-amylase and α-glucosidase inhibition, and antimicrobial activity were evaluated via minimum inhibitory concentration, minimum bactericidal concentration, and log reduction assays. The fermentation yielded 70.60-70.78 g/L freeze-dried postbiotics. Compositional analysis revealed EPS content of 652.99-654.17 µg/g, titratable acidity of 21.79-22.51 g/kg, total B-vitamin content of 387.37-390.67 mg/kg, total amino acids of 4366 ± 0.5 µg/kg, and over 32 distinct fatty acids. Antimicrobial testing showed complete inhibition of Bacillus cereus at 2.5 mg/mL, whereas higher concentrations were required for Salmonella enterica and Shigella sonnei. The postbiotics exhibited notable antioxidant activity (80.45% radical scavenging, IC₅₀ = 5.69 mg/mL) and apparent antidiabetic effects, inhibiting α-amylase by 84.39% (IC₅₀ = 8.29 mg/mL) and α-glucosidase by 72.51% (IC₅₀ = 12.42 mg/mL) under in vitro conditions. These results suggest the multifunctional bioactivity of postbiotics derived from mixed probiotic cultures, highlighting their potential as natural biopreservatives and functional food ingredients. However, in vivo validation is required to confirm these activities.

PMID 43052729
阅读全文 →
PubMedSystematic reviews2026-11-19

Direct oral anticoagulants versus vitamin K antagonists after pulmonary endarterectomy: a systematic review and meta-analysis.

Chen Yun-Ru YR, Liu Shou-Yao SY, Zhang Shuai S, Liu Zhao-Lan ZL et al.

Patients with chronic thromboembolic pulmonary hypertension who undergo pulmonary endarterectomy (PEA) require lifelong anticoagulation, yet the optimal regimen after surgery remains uncertain. Although vitamin K antagonists (VKAs) are traditionally used, direct oral anticoagulants (DOACs) have gained attention as potentially safer and more convenient alternatives. This systematic review and meta-analysis aims to evaluate the efficacy and safety of DOACs compared with VKAs in the post-PEA population. We systematically searched three English and four Chinese databases for relevant studies published up to March 2025. Risk of bias was evaluated using RoB 2 for RCTs and ROBINS-I for observational studies. Outcomes included venous thromboembolism (VTE), pulmonary embolism (PE) recurrence, bleeding events, and all-cause mortality. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Five studies (one randomized trial and four observational studies) involving 1986 patients were included. Overall, DOACs did not increase the risk of VTE recurrence compared with VKAs, but were associated with a higher likelihood of PE recurrence (RR = 2.99; 95% CI 1.51-5.93; I2 = 0%). At the same time, patients receiving DOACs experienced fewer major bleeding events (RR = 0.58; 95% CI 0.37-0.91; I2 = 0%) and lower all-cause mortality (RR = 0.51; 95% CI 0.35-0.75; I2 = 0%). Further analyses indicated no significant differences across outcomes in the rivaroxaban-only subgroup, whereas mixed-DOAC regimens were associated with significantly higher risks of both VTE and PE. In patients after PEA, DOACs were associated with lower risks of major bleeding and all-cause mortality, but may be less effective than VKAs in preventing PE recurrence. The current evidence-derived largely from observational studies and of low to very low certainty-does not support routine substitution of VKAs with DOACs in this setting. Clinical equipoise therefore remains, and further research is needed to clarify the optimal regimen. PROSPERO CRD420251008768.

PMID 43053203
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多folic acid + vitamin B6 + vitamin B12 + primorine